Invivyd plans to submit a Biologics License Application for COVID-19 antibody VYD2311 under the FDA's Accelerated Approval Program, with Phase 3 study data expected in October.

Observed price moves

• IVVD-4.68%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.